Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796289 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT00796289 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 350 participants.
The verdict
NCT00796289, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.
Interventions
- DRUG clomiphene citrate
- DRUG GnRH iontophoretic transdermal Lutrepatch
- DRUG placebo clomiphene citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796289
The ClinicalTrials.gov registry entry for NCT00796289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which clomiphene citrate is the first listed.
NCT00796289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796289 about?
NCT00796289 is a clinical study titled "Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females". The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.
What is the current status of trial NCT00796289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2009-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00796289?
The interventions under investigation include: clomiphene citrate (DRUG), GnRH iontophoretic transdermal Lutrepatch (DRUG), placebo clomiphene citrate (DRUG).
Who is sponsoring clinical trial NCT00796289?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.